BROAD SPECTRUM BETA-LACTAMASE INHIBITORS

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$160,232.00
Award Year:
2001
Program:
STTR
Phase:
Phase I
Contract:
PHS2001-2
Agency Tracking Number:
1R41AI048997-01
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
ALAMX, LLC
101 N WILMOT RD, STE 600, TUCSON, AZ 85711-3335, TUCSON, AZ, 85711
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
JOHN BUYNAK
(214) 768-2484
JBUYNAK@MAIL.SMU.EDU
Business Contact:
(520) 748-4465
RCT2CPM@AOL.COM
Research Institution:
SOUTHERN METHODIST UNIVERSITY

SOUTHERN METHODIST UNIVERSITY
DALLAS, TX, 76954

Nonprofit college or university
Abstract
DESCRIPTION (Adapted from the application): Penicillin-resistant bacteria pose a serious threat to human welfare. This project will generate new products designed to defeat resistant microorganisms. The most prevalent cause of bacterial resistance involves the destruction of the antibiotic with the enzyme B-lactamase. There are more than 255 known B-lactamases, which have been grouped into four classes: A through D. Historically, class A has been the most clinically important. However, the incidence of class C-mediated infections has increased dramatically in the past decade. Often such resistant infections can be defeated through the co-administration of an antibiotic and a B-lactamase inhibitor. However, current commercial B-lactamase inhibitors are effective only against class A enzymes. We have now identified and patented lead compounds which are simultaneously effective against both class A and class C B-lactamases. This project will develop those leads into viable commercial products. Collaborations with a number of academic researchers and pharmaceutical companies are in place, allowing access to representative B-lactamases as well as microbiological evaluations of these inhibitors. The objective is to develop products which have a broader spectrum than commercial antibiotic/inhibitor combinations. This will include either better overall activity or better activity against a subclass of clinically important organisms not targeted by current commercial products. PROPOSED COMMERCIAL APPLICATION: These inhibitors can be combined with the commercial beta-lactam antibiotic to broaden the spectrum of the antibiotic.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government